Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaniprevir + Peg-IFN/Ribavirin in Chronic Hepatitis C
NCT00704184Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of vaniprevir in hepatitis C virus infection (5 arms), sponsored by Merck & Co. Primary endpoints: Rapid Viral Response at 4 weeks, Number of Participants Experiencing an Adverse Event at 42 days and 1 more. Started Jul 2008; status: completed.
02
Drugs
vaniprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT00704184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00704184.